References
1. Wassef M, Blei F, Adams D, et al. Vascular Anomalies Classification:
Recommendations From the International Society for the Study of Vascular
Anomalies. Pediatrics . 2015;136(1):e203-214.
doi:10.1542/peds.2014-3673
2. ISSVA Classification of Vascular Anomalies ©2018
International Society for the Study of Vascular Anomalies Available at
“issva.org/classification” Accessed May 2023. Accessed May 5, 2023.
https://www.issva.org/classification
3. Putra J, Gupta A. Kaposiform haemangioendothelioma: a review
with emphasis on histological differential diagnosis. Pathology
(Phila) . 2017;49(4):356-362. doi:10.1016/j.pathol.2017.03.001
4. Ji Y, Chen S, Yang K, Xia C, Li L. Kaposiform
hemangioendothelioma: current knowledge and future perspectives.Orphanet J Rare Dis . 2020;15(1):39. doi:10.1186/s13023-020-1320-1
5. Kasabach HH, Merritt KK. Capillary Hemangioma With Extensive
Purpura: Report of a Case. Am J Dis Child . 1940;59(5):1063-1070.
doi:10.1001/archpedi.1940.01990160135009
6. Enjolras O, Wassef M, Mazoyer E, et al. Infants with
Kasabach-Merritt syndrome do not have “true” hemangiomas. J
Pediatr . 1997;130(4):631-640. doi:10.1016/s0022-3476(97)70249-x
7. Sarkar M, Mulliken JB, Kozakewich HP, Robertson RL, Burrows
PE. Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is
associated with Kaposiform hemangioendothelioma and not with common
infantile hemangioma. Plast Reconstr Surg . 1997;100(6):1377-1386.
doi:10.1097/00006534-199711000-00001
8. Gruman A, Liang MG, Mulliken JB, et al. Kaposiform
hemangioendothelioma without Kasabach-Merritt phenomenon. J Am
Acad Dermatol . 2005;52(4):616-622. doi:10.1016/j.jaad.2004.10.880
9. Croteau SE, Gupta D. The clinical spectrum of kaposiform
hemangioendothelioma and tufted angioma. Semin Cutan Med Surg .
2016;35(3):147-152. doi:10.12788/j.sder.2016.048
10. Adams DM, Trenor CC, Hammill AM, et al. Efficacy and Safety of
Sirolimus in the Treatment of Complicated Vascular Anomalies.PEDIATRICS . 2016;137(2):e20153257-e20153257.
doi:10.1542/peds.2015-3257
11. Drolet BA, Trenor CC, Brandão LR, et al. Consensus-Derived
Practice Standards Plan for Complicated Kaposiform Hemangioendothelioma.J Pediatr . 2013;163(1):285-291. doi:10.1016/j.jpeds.2013.03.080
12. Croteau SE, Liang MG, Kozakewich HP, et al. Kaposiform
hemangioendothelioma: atypical features and risks of Kasabach-Merritt
phenomenon in 107 referrals. J Pediatr . 2013;162(1):142-147.
doi:10.1016/j.jpeds.2012.06.044
13. Sakata N, Suenobu S ichi, Okano M, Ueda S, Kimura M, Takemura
T. Impact of sirolimus treatment for refractory kaposiform
hemangioendothelioma with exacerbation of the disease 10 years after
initial diagnosis. Rare Tumors . 2018;10.
doi:10.1177/2036361318776185
14. Schaefer BA, Wang D, Merrow AC, Dickie BH, Adams DM. Long-term
outcome for kaposiform hemangioendothelioma: A report of two cases.Pediatr Blood Cancer . 2017;64(2):284-286. doi:10.1002/pbc.26224
15. Tower R l. Kaposiform haemangioendothelioma: new insights and
old problems. Br J Dermatol . 2018;179(2):253-254.
doi:10.1111/bjd.16834
16. Adams DM, Wentzel MS. The role of the hematologist/oncologist
in the care of patients with vascular anomalies. Pediatr Clin
North Am . 2008;55(2):339-355, viii. doi:10.1016/j.pcl.2008.01.007
17. Ricci KW. Advances in the Medical Management of Vascular
Anomalies. Semin Interv Radiol . 2017;34(3):239-249.
doi:10.1055/s-0037-1604297
18. Adams DM, Ricci KW. Vascular Anomalies: Diagnosis of
Complicated Anomalies and New Medical Treatment Options. Hematol
Oncol Clin North Am . 2019;33(3):455-470. doi:10.1016/j.hoc.2019.01.011
19. Liu XH, Li JY, Qu XH, et al. Treatment of kaposiform
hemangioendothelioma and tufted angioma. Int J Cancer .
2016;139(7):1658-1666. doi:10.1002/ijc.30216
20. Haisley-Royster C, Enjolras O, Frieden IJ, et al.
Kasabach-merritt phenomenon: a retrospective study of treatment with
vincristine. J Pediatr Hematol Oncol . 2002;24(6):459-462.
doi:10.1097/00043426-200208000-00010
21. Barlow CF, Priebe CJ, Mulliken JB, et al. Spastic diplegia as
a complication of interferon Alfa-2a treatment of hemangiomas of
infancy. J Pediatr . 1998;132(3 Pt 1):527-530.
doi:10.1016/s0022-3476(98)70034-4
22. Morad AB, McClain KL, Ogden AK. The role of tranexamic acid in
the treatment of giant hemangiomas in newborns. Am J Pediatr
Hematol Oncol . 1993;15(4):383-385.
23. Hauer J, Graubner U, Konstantopoulos N, Schmidt S, Pfluger T,
Schmid I. Effective treatment of kaposiform hemangioendotheliomas
associated with Kasabach-Merritt phenomenon using four-drug regimen.Pediatr Blood Cancer . 2007;49(6):852-854. doi:10.1002/pbc.20750
24. Blei F, Karp N, Rofsky N, Rosen R, Greco MA. Successful
multimodal therapy for kaposiform hemangioendothelioma complicated by
Kasabach-Merritt phenomenon: case report and review of the literature.Pediatr Hematol Oncol . 1998;15(4):295-305.
doi:10.3109/08880019809014013
25. Blatt J, Stavas J, Moats‐Staats B, Woosley J, Morrell DS.
Treatment of childhood kaposiform hemangioendothelioma with sirolimus.Pediatr Blood Cancer . 2010;55(7):1396-1398. doi:10.1002/pbc.22766
26. Hammill AM, Wentzel M, Gupta A, et al. Sirolimus for the
treatment of complicated vascular anomalies in children. Pediatr
Blood Cancer . 2011;57(6):1018-1024. doi:10.1002/pbc.23124
27. Peng S, Yang K, Xu Z, Chen S, Ji Y. Vincristine and sirolimus
in the treatment of kaposiform haemangioendothelioma. J Paediatr
Child Health . 2019;55(9):1119-1124. doi:10.1111/jpc.14370
28. Ji Y, Chen S, Xiang B, et al. Sirolimus for the treatment of
progressive kaposiform hemangioendothelioma: A multicenter retrospective
study. Int J Cancer . 2017;141(4):848-855. doi:10.1002/ijc.30775
29. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium:
Building an international community of software platform partners.J Biomed Inform . 2019;95:103208. doi:10.1016/j.jbi.2019.103208
30. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response
evaluation criteria in solid tumours: Revised RECIST guideline (version
1.1). Eur J Cancer . 2009;45(2):228-247.
doi:10.1016/j.ejca.2008.10.026
31. Ji Y, Chen S, Zhou J, et al. Sirolimus plus prednisolone vs
sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized
clinical trial. Blood . 2022;139(11):1619-1630.
doi:10.1182/blood.2021014027
32. Ji Y, Yang K, Peng S, et al. Kaposiform haemangioendothelioma:
clinical features, complications and risk factors for Kasabach-Merritt
phenomenon. Br J Dermatol . 2018;179(2):457-463.
doi:10.1111/bjd.16601
33. Rodriguez V, Lee A, Witman PM, Anderson PA. Kasabach-merritt
phenomenon: case series and retrospective review of the mayo clinic
experience. J Pediatr Hematol Oncol . 2009;31(7):522-526.
doi:10.1097/MPH.0b013e3181a71830
TABLE 1 Demographic and Clinical Characteristics of Patients with KHE/TA